Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced Breast Cancer × capivasertib × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 17 Triple Negative Breast Neoplasms 5 Neoplasm Metastasis 2 Disease Progression 2 Uterine Cervical Neoplasms 1 Prostatic Neoplasms 1 Ovarian Neoplasms 1 Melanoma 1 Hereditary Sensory and Autonomic Neuropathies 1 Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer) 1 Estrogen Receptor Positive Breast Cancer 1 Endometrial Neoplasms 1 Advanced Breast Cancer 1

Interventions

Fulvestrant 17 Letrozole 9 Anastrozole 7 Capecitabine 5 olaparib 4 Docetaxel 4 pyrotinib 3 palbociclib 3 Vinorelbine 3 Paclitaxel 3 Goserelin 3 Aromatase Inhibitors 3 trastuzumab deruxtecan 2 sacituzumab govitecan 2 exemestane 2 eribulin 2 dalpiciclib 2 Trastuzumab 2 FCN-437c 2 Dasatinib 2 Alpelisib 2 Albumin-Bound Paclitaxel 2 vandetanib 1 talazoparib 1 sonidegib 1 ribociclib 1 neratinib 1 liposomal doxorubicin 1 irinotecan sucrosofate 1 entinostat 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03182634 2019-01-22

plasmaMATCH

Institute of Cancer Research, United Kingdom

Phase 2 Unknown

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡